{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:04:30Z","timestamp":1782299070925,"version":"3.54.5"},"reference-count":61,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre (Poland)","award":["UMO-2020\/01\/0\/NZ6\/00152"],"award-info":[{"award-number":["UMO-2020\/01\/0\/NZ6\/00152"]}]},{"name":"National Science Centre (Poland)","award":["UMO\/2018\/31\/F\/NZ1\/03891"],"award-info":[{"award-number":["UMO\/2018\/31\/F\/NZ1\/03891"]}]},{"name":"National Science Centre (Poland)","award":["UMO-2020\/01\/0\/NZ6\/00152"],"award-info":[{"award-number":["UMO-2020\/01\/0\/NZ6\/00152"]}]},{"name":"National Science Centre (Poland)","award":["UMO\/2018\/31\/F\/NZ1\/03891"],"award-info":[{"award-number":["UMO\/2018\/31\/F\/NZ1\/03891"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>One of the groups most vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is healthcare workers (HCWs) who have direct contact with suspected and confirmed coronavirus diseases 2019 (COVID-19) patients. Therefore, this study aimed to (i) conduct a longitudinal analysis of the seroprevalence of SARS-CoV-2 infection among HCWs working in two healthcare units (HCUs) in Poland and (ii) identify anti-SARS-CoV-2 IgG antibody (Ab) response factors following infection and anti-COVID-19 vaccination. The overall seroprevalence increased from 0% at baseline in September 2020 to 37.8% in December 2020. It reached 100% in February 2021 after BNT126b2 (Pfizer New York, NY, USA\/BioNTech Mainz, Germany) full vaccination and declined to 94.3% in September 2021. We observed significant differences in seroprevalence between the tested high- and low-risk infection HCUs, with the highest seropositivity among the midwives and nurses at the Gynecology and Obstetrics Ward, who usually have contact with non-infectious patients and may not have the proper training, practice and personal protective equipment to deal with pandemic infections, such as SARS-CoV-2. We also found that anti-SARS-CoV-2 Ab levels after coronavirus infection were correlated with disease outcomes. The lowest Ab levels were found among HCWs with asymptomatic coronavirus infections, and the highest were found among HCWs with severe COVID-19. Similarly, antibody response after vaccination depended on previous SARS-CoV-2 infection and its course: the highest anti-SARS-CoV-2 Ab levels were found in vaccinated HCWs after severe COVID-19. Finally, we observed an approximately 90\u201395% decrease in anti-SARS-CoV-2 Ab levels within seven months after vaccination. Our findings show that HCWs have the highest risk of SARS-CoV-2 infection, and due to antibody depletion, extra protective measures should be undertaken. In addition, in the context of the emergence of new pathogens with pandemic potential, our results highlight the necessity for better infectious disease training and regular updates for the low infection risk HCUs, where the HCWs have only occasional contact with infectious patients.<\/jats:p>","DOI":"10.3390\/vaccines10101576","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:08:09Z","timestamp":1663718889000},"page":"1576","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland\u2014Before and after BNT126b2 mRNA COVID-19 Vaccination"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-3746","authenticated-orcid":false,"given":"Dagny","family":"Lorent","sequence":"first","affiliation":[{"name":"Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Nowak","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Luwa\u0144ski","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Ward, District Hospital in Wrzesnia, 62-300 Wrzesnia, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pisarska-Krawczyk","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Ward, District Hospital in Wrzesnia, 62-300 Wrzesnia, Poland"},{"name":"Department of Nursery, The President Stanislaw Wojciechowski Calisia University, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4731-0658","authenticated-orcid":false,"given":"Magdalena","family":"Figlerowicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Child Neurology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7223","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zmora","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry Polish Academy of Sciences, 61-704 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, July 25). Coronavirus. Available online: https:\/\/www.who.int\/health-topics\/coronavirus."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwaa191","article-title":"COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes","volume":"190","author":"Franco","year":"2021","journal-title":"Am. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhin.2020.11.008","article-title":"Seroprevalence of SARS-CoV-2 Antibodies and Associated Factors in Healthcare Workers: A Systematic Review and Meta-Analysis","volume":"108","author":"Galanis","year":"2021","journal-title":"J. Hosp. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lorent, D., Nowak, R., Roxo, C., Lenartowicz, E., Makarewicz, A., Zaremba, B., Nowak, S., Kuszel, L., Stefaniak, J., and Kierzek, R. (2021). Prevalence of Anti-SARS-CoV-2 Antibodies in Pozna\u0144, Poland, after the First Wave of the COVID-19 Pandemic. Vaccines, 9.","DOI":"10.1101\/2021.03.29.21254544"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14760584.2021.1875824","article-title":"COVID-19 Vaccine: Where Are We Now and Where Should We Go?","volume":"20","author":"Soleimanpour","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kaur, S.P., and Gupta, V. (2020). COVID-19 Vaccine: A Comprehensive Status Report. Virus Res., 288.","DOI":"10.1016\/j.virusres.2020.198114"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14760584.2021.1949293","article-title":"COVID-19 Vaccines: Concerns beyond Protective Efficacy and Safety","volume":"20","author":"Lai","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A Comprehensive Analysis of the Efficacy and Safety of COVID-19 Vaccines","volume":"29","author":"Cai","year":"2021","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sharif, N., Alzahrani, K.J., Ahmed, S.N., and Dey, S.K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.714170"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M.H., Turner, D.L., and Turner, R.J. (2021). Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 9.","DOI":"10.2139\/ssrn.3812422"},{"key":"ref_11","unstructured":"(2022, July 25). MRNA-1273 Vaccine (Moderna) against COVID-19 Background Document (Draft). Available online: https:\/\/www.who.int\/publications-detail-redirect\/mrna-1273-vaccine-(moderna)-against-covid-19-background-document-(draft)."},{"key":"ref_12","unstructured":"(2022, July 25). Background Document on MRNA Vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Available online: https:\/\/www.who.int\/publications-detail-redirect\/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19."},{"key":"ref_13","unstructured":"(2022, July 25). The Role of Community Health Workers in COVID-19 Vaccination: Implementation Support Guide. Available online: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-NDVP-CHWs-role-2021.1."},{"key":"ref_14","unstructured":"(2022, August 22). Narodowy Program Szczepie\u0144 Przeciw COVID-19\u2014Szczepienie Przeciwko COVID-19\u2014Portal Gov.pl, Available online: https:\/\/www.gov.pl\/web\/szczepimysie\/narodowy-program-szczepien-przeciw-covid-19."},{"key":"ref_15","unstructured":"(2022, July 25). Mapa Zara\u017ce\u0144\u2014COVID-HUB. Available online: https:\/\/covidhub.psnc.pl\/mapa\/."},{"key":"ref_16","unstructured":"(2022, August 22). Zaszczepionych 93,24% Lekarzy. Available online: http:\/\/www.mp.pl\/social\/article\/277067."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of MRNA BNT162b2 COVID-19 Vaccine up to 6 Months in a Large Integrated Health System in the USA: A Retrospective Cohort Study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kasztelewicz, B., Janiszewska, K., Burzy\u0144ska, J., Szyd\u0142owska, E., Migda\u0142, M., and Dzier\u017canowska-Fangrat, K. (2021). Prevalence of IgG Antibodies against SARS-CoV-2 among Healthcare Workers in a Tertiary Pediatric Hospital in Poland. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249550"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bu\u0142dak, R.J., Wo\u017aniak-Grygiel, E., W\u0105sik, M., Kasperczyk, J., Gawrylak-Dryja, E., Mond-Paszek, R., Konka, A., Badura-Brzoza, K., Fronczek, M., and Golec, M. (2021). SARS-CoV-2 Antibody Screening in Healthcare Workers in Non-Infectious Hospitals in Two Different Regions of Southern Poland (Upper Silesia and Opole Voivodeships): A Prospective Cohort Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18084376"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Korona-G\u0142owniak, I., Mielnik, M., Podgajna, M., Grywalska, E., Hus, M., Matuska, K., Wojtysiak-Duma, B., Duma, D., Glowniak, A., and Malm, A. (2022). SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19042319"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Piccoli, L., Ferrari, P., Piumatti, G., Jovic, S., Rodriguez, B.F., Mele, F., Giacchetto-Sasselli, I., Terrot, T., Silacci-Fregni, C., and Cameroni, E. (2021). Risk Assessment and Seroprevalence of SARS-CoV-2 Infection in Healthcare Workers of COVID-19 and Non-COVID-19 Hospitals in Southern Switzerland. Lancet Reg. Health\u2014Eur., 1.","DOI":"10.1016\/j.lanepe.2020.100013"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104437","DOI":"10.1016\/j.jcv.2020.104437","article-title":"SARS-CoV-2-Specific Antibody Detection in Healthcare Workers in Germany with Direct Contact to COVID-19 Patients","volume":"128","author":"Korth","year":"2020","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Psichogiou, M., Karabinis, A., Pavlopoulou, I.D., Basoulis, D., Petsios, K., Roussos, S., Pratikaki, M., Jahaj, E., Protopapas, K., and Leontis, K. (2020). Antibodies against SARS-CoV-2 among Health Care Workers in a Country with Low Burden of COVID-19. PLoS ONE, 15.","DOI":"10.1101\/2020.06.23.20137620"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brant-Zawadzki, M., Fridman, D., Robinson, P.A., Zahn, M., Chau, C., German, R., Breit, M., Bock, J.R., and Hara, J. (2020). SARS-CoV-2 Antibody Prevalence in Health Care Workers: Preliminary Report of a Single Center Study. PLoS ONE, 15.","DOI":"10.1101\/2020.07.20.20158329"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Brant-Zawadzki, M., Fridman, D., Robinson, P.A., Zahn, M., Chau, C., German, R., Breit, M., Burke, E., Bock, J.R., and Hara, J. (2021). Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers. Open Forum Infect. Dis., 8.","DOI":"10.1093\/ofid\/ofab015"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bogogiannidou, Z., Vontas, A., Dadouli, K., Kyritsi, M.A., Soteriades, S., Nikoulis, D.J., Mouchtouri, V.A., Koureas, M., Kazakos, E.I., and Spanos, E.G. (2020). Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies, Greece, March and April 2020. Eurosurveillance, 25.","DOI":"10.2807\/1560-7917.ES.2020.25.31.2001369"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.15585\/mmwr.mm6929e1","article-title":"Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample\u2014Indiana, April 25\u201329, 2020","volume":"69","author":"Menachemi","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.15585\/mmwr.mm6932a4","article-title":"Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample\u2014Oregon, May 11\u2013June 15, 2020","volume":"69","author":"Sutton","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zejda, J.E., Bro\u017cek, G.M., Kowalska, M., Bara\u0144ski, K., Kaleta-Pilarska, A., Nowakowski, A., Xia, Y., and Buszman, P. (2021). Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Random Sample of Inhabitants of the Katowice Region, Poland. Int. J. Environ. Res. Public Health, 18.","DOI":"10.1183\/13993003.congress-2021.PA915"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJMc2101951","article-title":"BNT162b2 MRNA Covid-19 Vaccine Effectiveness among Health Care Workers","volume":"384","author":"Benenson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bianchi, F.P., Tafuri, S., Migliore, G., Vimercati, L., Martinelli, A., Lobifaro, A., Diella, G., Stefanizzi, P., and on behalf of the Control Room Working Group (2021). BNT162b2 MRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study. Vaccines, 9.","DOI":"10.2139\/ssrn.3894959"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2021.11.061","article-title":"COVID-19 Vaccine Uptake, Effectiveness, and Waning in 82,959 Health Care Workers: A National Prospective Cohort Study in Wales","volume":"40","author":"Bedston","year":"2022","journal-title":"Vaccine"},{"key":"ref_35","first-page":"1242","article-title":"The Seroprevalence of SARS-CoV-2 Antibodies among Health Care Workers before the Era of Vaccination: A Systematic Review and Meta-Analysis","volume":"27","author":"Madran","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ebinger, J.E., Joung, S., Liu, Y., Wu, M., Weber, B., Claggett, B., Botting, P.G., Sun, N., Driver, M., and Kao, Y.H. (2022). Demographic and Clinical Characteristics Associated with Variations in Antibody Response to BNT162b2 COVID-19 Vaccination among Healthcare Workers at an Academic Medical Centre: A Longitudinal Cohort Analysis. BMJ Open, 12.","DOI":"10.1136\/bmjopen-2021-059994"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Alishaq, M., Nafady-Hego, H., Jeremijenko, A., Ajmi, J.A.A., Elgendy, M., Vinoy, S., Fareh, S.B., Plaatjies, J.V., Nooh, M., and Alanzi, N. (2021). Risk Factors for Breakthrough SARS-CoV-2 Infection in Vaccinated Healthcare Workers. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258820"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/anae.15229","article-title":"A Cross-Sectional Study of Immune Seroconversion to SARS-CoV-2 in Frontline Maternity Health Professionals","volume":"75","author":"Bampoe","year":"2020","journal-title":"Anaesthesia"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Coxon, K., Turienzo, C.F., Kweekel, L., Goodarzi, B., Brigante, L., Simon, A., and Lanau, M.M. (2020). The Impact of the Coronavirus (COVID-19) Pandemic on Maternity Care in Europe. Midwifery, 88.","DOI":"10.1016\/j.midw.2020.102779"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schmitt, N., Mattern, E., Cignacco, E., Seliger, G., K\u00f6nig-Bachmann, M., Striebich, S., and Ayerle, G.M. (2021). Effects of the Covid-19 Pandemic on Maternity Staff in 2020\u2014A Scoping Review. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-07377-1"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Russell, A., Hsu, E.B., Fenstermacher, K.Z.J., Ricketts, E.P., Dashler, G., Chen, A., Shaw-Saliba, K., Caturegli, P.P., Pekosz, A., and Rothman, R.E. (2022). Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore. Healthcare, 10.","DOI":"10.3390\/healthcare10030576"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune Determinants of COVID-19 Disease Presentation and Severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Talaei, M., Faustini, S., Holt, H., Jolliffe, D.A., Vivaldi, G., Greenig, M., Perdek, N., Maltby, S., Bigogno, C.M., and Symons, J. (2022). Determinants of Pre-Vaccination Antibody Responses to SARS-CoV-2: A Population-Based Longitudinal Study (COVIDENCE UK). BMC Med., 20.","DOI":"10.1186\/s12916-022-02286-4"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zimmermann, P., and Curtis, N. (2019). Factors That Influence the Immune Response to Vaccination. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00084-18"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., and Pa\u0142gan, K. (2021). Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells, 10.","DOI":"10.21203\/rs.3.rs-388040\/v3"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity","volume":"183","author":"Ramirez","year":"2020","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 MRNA Vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex Differences in Immune Responses That Underlie COVID-19 Disease Outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmer\u00f3n, G., Molina, M.J., Vidal, M., Barrios, D., and Mitchell, R.A. (2022). Determinants of Early Antibody Responses to COVID-19 MRNA Vaccines in a Cohort of Exposed and Na\u00efve Healthcare Workers. EBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103805"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS-CoV-2 Infection and Vaccination","volume":"185","author":"Nielsen","year":"2022","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc2103825","article-title":"SARS-CoV-2 Antibody Response in Persons with Past Natural Infection","volume":"385","author":"Anichini","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3389\/fpubh.2021.778243","article-title":"Previous COVID-19 Infection and Antibody Levels After Vaccination","volume":"9","author":"Ali","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal Analysis of Antibody Dynamics in COVID-19 Convalescents Reveals Neutralizing Responses up to 16 Months after Infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wolszczak-Biedrzycka, B., Bie\u0144kowska, A., and Dorf, J. (2021). Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection. Vaccines, 9.","DOI":"10.3390\/vaccines9121508"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Anastassopoulou, C., Antoni, D., Manoussopoulos, Y., Stefanou, P., Argyropoulou, S., Vrioni, G., and Tsakris, A. (2022). Age and Sex Associations of SARS-CoV-2 Antibody Responses Post BNT162b2 Vaccination in Healthcare Workers: A Mixed Effects Model across Two Vaccination Periods. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266958"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","article-title":"Population Antibody Responses Following COVID-19 Vaccination in 212,102 Individuals","volume":"13","author":"Ward","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., De Virgilio, A., De Marco, F., and Di Domenico, E.G. (2021). Initial Observations on Age, Gender, BMI and Hypertension in Antibody Responses to SARS-CoV-2 BNT162b2 Vaccine. EClinicalMedicine, 36.","DOI":"10.1016\/j.eclinm.2021.100928"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease Severity Dictates SARS-CoV-2-Specific Neutralizing Antibody Responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"R\u00f6ltgen, K., Powell, A.E., Wirz, O.F., Stevens, B.A., Hogan, C.A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M.K., and Huang, C. (2020). Defining the Features and Duration of Antibody Responses to SARS-CoV-2 Infection Associated with Disease Severity and Outcome. Sci. Immunol., 5.","DOI":"10.1126\/sciimmunol.abe0240"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m, P., Ballin, M., and Nordstr\u00f6m, A. (2022). Effectiveness of a Fourth Dose of MRNA COVID-19 Vaccine against All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden. Lancet Reg. Health\u2014Eur., 21.","DOI":"10.1016\/j.lanepe.2022.100466"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1576\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:36:00Z","timestamp":1760142960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101576"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101576","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}